Skip to main content
Springer Nature Link
Log in

Provocative tests with psychostimulant drugs in schizophrenia

  • Original Investigations
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

The psychotogenic effects of psychostimulant drugs have provided a major line of evidence in support of the DA hypothesis of schizophrenia. To evaluate the effects of psychostimulant (PS) drugs inschizophrenia and the clinical variables which may influence their expression, we reviewed 36 studies of PS drugs in patients with schizophrenia. Approximately 40% evidence a psychotogenic response to PS administration in doses that are subpsychotogenic in normals. Specific clinical variables appear to modify this response, including diagnosis, degree and type of psychopathology, stage of illness and pharmacologic status at the time of testing. Non-amphetamine-like PS drugs, e.g., methylphenidate, appear to have greater psychotogenic potency than amphetamine-like PS drugs. These results suggest the presence of a subgroup of schizophrenic patients who exhibit psychotic symptom activation with PS in a state dependent or independent fashion. This biologic phenomenon may be clinically exploitable and should be investigated further.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Anderson EW (1938) Further observations on benzedrine. Br Med J [Clin Res] 2:60–64

    Google Scholar 

  • Andreasen NC (1982) Negative symptoms in schizophrenia. Arch Gen Psychiatry 39:784–788

    Google Scholar 

  • Angrist BM, Gershon S (1970) The phenomenology of experimentally induced amphetamine psychosis-Preliminary observations. Biol Psychiatry 2:95–107

    Google Scholar 

  • Angrist B, vanKammen DP (1984) CNS stimulants as tools in the study of schizophrenia. Trends NeuroSci 7:388–390

    Google Scholar 

  • Angrist B, Sathananthan G, Wilk S, Gershon S (1974) Amphetamine psychosis: behavioral and biochemical aspects. J Psychiatr Res 11:13–23

    Google Scholar 

  • Angrist B, Rotrosen J, Gershon S (1980a) Differential effects of amphetamine and neuroleptics on positive vs. negative symptoms in schizophrenia. Psychopharmacology 72:17–19

    Google Scholar 

  • Angrist B, Rotrosen J, Gershon S (1980b) Responses to apomorphine, amphetamine, and neuroleptics. Psychpharmacology 67:31–38

    Google Scholar 

  • Angrist B, Peselow E, Rubinstein M, Wolkin A, Rotrosen J (1985) Amphetamine response and relapse risk after depot neuroleptic discontinuation. Psychopharmacology 85:277–283

    Google Scholar 

  • Askar AM, Rakhawy YT, Shaheen O (1970) The quantitative assessment of therapeutic effect of methamphetamine on psychiatric patients. J Egypt Med Assoc 53:563–577

    Google Scholar 

  • Belart VW (1942) Pathogenetisches und therapeutisches aus Pervitinversuchen bei Schizophrenie. Schweiz Med Wochenschr 2:41–43

    Google Scholar 

  • Bell DS (1973) The experimental reproduction of amphetamine psychosis. Arch Gen Psychiatry 29:35–40

    Google Scholar 

  • Bischoff A (1951) Über eine therapeutische Verwendung der sogenannten “week-amine” an der Behandlung schizophrener Erregungszustände, Monatsschr Psychiatr Neurol 121:329–344

    Google Scholar 

  • Brown WA, Corrieveau DP, Ebert MH (1978) Acute psychologic and neuroendocrine effects of dextroamphetamine and methylphenidate. Psychopharmacology 58:189–195

    Google Scholar 

  • Buchsbaum MC, Rieder RO (1979) Biologic heterogenety and psychiatric research. Arch Gen Psychiatry 36:1163–1169

    Google Scholar 

  • Connell PH (1958) Amphetamine psychosis. Maudsley Monograph No. 5. Chapman Hall, London

    Google Scholar 

  • Creese I, Burt DR, Snyder SH (1976) Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs. Science 192:481–483

    Google Scholar 

  • Crow TJ (1980) Molecular pathology of schizophrenia: More than one disease process? Br Med J 6207:66–68

    Google Scholar 

  • Davidoff E, Reifenstein EC (1939) Treatment of schizophrenia with sympathomimetic drugs: Benzedrine sulfate. Am J Psychiatry 95:127–143

    Google Scholar 

  • Delay J (1949) Section of psychiatry, pharmacological explorations of the personality: narco-analysis and methedrine shock. Proc R Soc Med 62:491–496

    Google Scholar 

  • Dommisse CS, Schulz C, Narasimhachari N, Blackard WG, Hamer RN (1984) The neuroendocrine and behavioral response to dextroamphetamine in normal individuals. Biol Psychiatry 19:1305–1315

    Google Scholar 

  • Fawcett J, Siomopoulos V (1971) Dextroamphetamine response as a possible predictor of improvement with tricyclic therapy in depression. Arch Gen Psychiatry 25:247–255

    Google Scholar 

  • Ferris R, Tang F, Maxwell R (1972) A comparison of the capacities of isomers of amphetamine, deoxypiradrol and methylphenidate to inhibit the uptake of tritiated catecholamines into rat cerebral cortex slices, synaptosomal preparations of rat cerebral cortex, hypothalamus and striatum and into adrenergic nerves of rabbit aorta. J Pharmacol Exp Ther 181:407–416

    Google Scholar 

  • Flugel FE (1938) Medikamentöse Beeinflussung psychischer Hemmungszustaende. Klin Wochenschr 17. Jahrgang Nr 37:1286–1288

    Google Scholar 

  • Fung YK, Uretsky J (1982) The differential effects of amphetamine and methylphenidate eon the biosynthesis of [3H] dopa from [3H]tyrosine in mouse striata in vivo. J Pharm Pharmacol 531–532

  • Gottlieb JS, Coburn FE (1944) Psychopharmacologic study of schizophrenia and depressions. Arch Neurol Psychiatry 51:260–263

    Google Scholar 

  • Gottliewb JS, Krause H, Friedinger AW (1945) Psychopharmacologic study of schizophrenia and depressions. II. Comparison of tolerance to sodium amytal and amphetamine sulfate. Arch Neurol Psychiatry 54:372–377

    Google Scholar 

  • Griffith JD, Cavanaugh J, Held J, Oates JA (1972) Dextroamphetamine: Evaluation of psychotomimmetic properties in man. Arch Gen Psychiatry 26:97–100

    Google Scholar 

  • Groves PM, Rebec GV (1976) Biochemistry and behavior: Some central actions of amphetamine and antipsychotic drugs. Annu Rev Psychol 27:91–127

    Google Scholar 

  • Guile LA (1963) Intravenous methylphenidate — a pilot study. Med J Aust 2:93–97

    Google Scholar 

  • Gutman E, Sargant W (1937) Observations on benzedrine. Br Med J 1:1013–1015

    Google Scholar 

  • Halbreich U, Asnis G, Ross D, Endicott J (1981) Amphetamine-induced dysphoria in postmenopausal women. Br J Psychiatry 138:470–473

    Google Scholar 

  • Haracz JL (1982) The dopamine hypothesis: An overview of studies with schizophrenic patients. Schizophr Bull 8:438–469

    Google Scholar 

  • Hauger RL, Hulihan-Giblin B, Janowsky A, Angel I, Berger P, Luu MD, Schweri MM, Vocci F, Skolnick P, Paul SM (1986) CNS recognition sites for psychomotor stimulants: methylphenidate and amphetamine (in press)

  • Hope JM, Callaway E, Sands SL (1951) Intravenous pervitin and the psychopathology of schizophrenia. Dis Nerv Syst 12:67–72

    Google Scholar 

  • Hornykiewicz O (1982) Brain catecholamines in schizophrenia — a good case for noradrenaline. Nature 299:484–486

    Google Scholar 

  • Janowsky DS, El-Yousef MK, Davis JM, Sekerke J (1973) Provocation of schizophrenic symptoms by intravenous administration of methylphenidate. Arch Gen Psychiatry 28:185–191

    Google Scholar 

  • Janowsky DS, Davis JM (1976) Methylphenidate, dextroamphetamine, and levamphetamine. Effects on schizophrenic symptoms. Arch Gen Psychiatry 33:304–308

    Google Scholar 

  • Janowsky DS, Huey L, Storms L, Judd L (1977) Methylphenidate hydrochloride effects on psychological tests in acute schizophrenic and non-psychotic patients. Arch Gen Psychiatry 34:189–194

    Google Scholar 

  • Janowsky DS, Leichner P, Clopton P, Parka D, Judd L, Huey L (1978) Comparison of oral and intravenous methylphenidate. Psychopharmacology 59:75–78

    Google Scholar 

  • Johnstone EC, Crow TJ, Frith CD, Carney MWP, Price JS (1978) Mechanism of the antipsychotic effect in the treatment of acute schizophrenia. Lancet 2:848–851

    Google Scholar 

  • Jonas AD (1954) The adjunctive use of an intravenous amphetamine derivative in psychotherapy. J Nerv Ment Dis 119:135–147

    Google Scholar 

  • Jonsson LE (1972) Pharmacological blockade of amphetamine effects in amphetamine dependent subjects. Eur J Clin Pharmacol 4:206–211

    Google Scholar 

  • Kiloh LG, Neilson M, Andrews G (1974) Response of depressed patients to methylamphetamine. Br J Psychiatry 125:496–499

    Google Scholar 

  • Kornetsky C (1976) Hyporesponsivity of chronic schizophrenic patients to dextroamphetamine. Arch Gen Psychiatry 33:1425–1428

    Google Scholar 

  • Lehmann HE, Ban TA (1964) Notes from the log-book of a psychopharmacological research unit II. Can Psychiatr Assoc J 9:111–113

    Google Scholar 

  • Levine J, Rinkel M, Greenblatt M (1978) Psychological and physiological effects of intravenous pervitin. Am J Psychiatry 105:429–434

    Google Scholar 

  • Liddell DW, Weil-Malherbe H (1953) The effects of methedrine and of lysergic acid diethylamine on mental processes and on the blood adrenaline level. J Neurol Neurosurg Psychiatry 16:713

    Google Scholar 

  • Lieberman JA, Kane JM, Gadaleta D, Brenner R, Lesser MS, Kinon B (1984) Methylphenidate challenge as a predictor of relapse in schizophrenia. Am J Psychiatry 141:633–638

    Google Scholar 

  • Lieberman JA, Cooper T, Kinon B, Novacenko H, Harris P, Kane J (1985) Biochemical and clinical responses of schizophrenic patients to pharmacologic challenge tests on and off neuroleptic treatment. Presented at the Annual Meeting of the American College of Neuropsychopharmacology, Hawaii, December 9–13

  • Mackay A, Crow TJ (1980) Positive and negative schizophrenic symptoms and the role of dopamine. Br J Psychiatry 137:379–386

    Google Scholar 

  • Martin WR, Sloan JW, Sapira JD, Janinski DR (1971) Psychologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phennetrazine, and methylphenidate in man. Clin Pharmacol Ther 12:245–258

    CAS  PubMed  Google Scholar 

  • McMillen BA (1983) CNS stimulants: two distinct mechanisms of action for amphetamine-like drugs. TIPS 429–432

  • Meltzer HY, Stahl SM (1976) The dopamine hypothesis of schizophrenia: A review. Schizophr Bull 2:19–76

    Google Scholar 

  • Merali Z, Toth G (1982) Effects of fluphenazine decanoate (a long-acting phenothiazine) on serum prolactin and amphetamine-induced behavioural changes. Pharmacol Biochem Behav 17:25–30

    Google Scholar 

  • Modell W, Hussar AE (1965) Failure of dextroamphetamine sulfate to influence eating and sleeping patterns in obese schizophrenic patients. JAMA 194:95–98

    Google Scholar 

  • Moore KE (1978) The actions of amphetamine on neurotransmitters: A brief review. Biol Psychiatry 12:451–462

    Google Scholar 

  • Nielsen JA, Chapin DS, Moore KE (1983) Differential effects of d-amphetamine, d-phenylethylamine, cocaine and methylphenidate on the rate of dopamine synthesis in terminals of nigrostriatal and mesolimbic neurons and on the efflux of dopamine metabolites into cerbroventricular perfusates of rats. Life Sci 33:1899–1907

    Google Scholar 

  • Pennes HH (1954) Clinical reactions of schizophrenics to sodium amytal, pervitin hydrochloride, mescaline sulfate, and d-lysergic acid diethylamide (LSD25). J Nerv Ment Dis 119:95–111

    Google Scholar 

  • Rall TW (1980) Central Nervous System Stimulants. In: Goodman LS, Gilman A (eds) The pharmacological basis of therapeutics. Macmillan, New York, pp 592–607

    Google Scholar 

  • Scheel-Krüger J (1971) Comparative studies of various amphetamine analogue demonstrating different interactions with the metabolism of the catecholamines in the brain. Eur J Pharmacol 14:47–59

    Google Scholar 

  • Schube PG, McManamy MC, Trapp CE (1937) The effect of benzedrine sulphate on certain abnormal mental states. Am J Psychiatry 94:27–32

    Google Scholar 

  • Seeman P, Lee T, Chau-Wong M, Wong K (1976) Antipsychotic drug doses and neuroleptic-dopamine receptors. Nature 261:717–719

    Google Scholar 

  • Shore PA, McMillen BA, Miller HH, Sanghera MK, Kiser RS, German DC (1979) The dopamine neuronal storage system and non-amphetamine psychotogenic stimulants: A model for psychosis. In: Usdin E, Kopin IJ, Barchas J (eds) Catecholamines: basic and clinical frontiers. Pergamon, New York, pp 722–727

    Google Scholar 

  • Simon JL, Taube H (1946) A preliminary study on the use of methedrine on psychiatric diagnosis. J Nerv Ment Dis 104:593–596

    Google Scholar 

  • Snyder SH (1973) Amphetamine psychosis: A “model” schizophrenia mediated by catecholamines. Am J Psychiatry 130:61–67

    Google Scholar 

  • Snyder SH (1976) The dopamine hypothesis of schizophrenia: Focus on the dopamine receptor. Am J Psychiatry 133:197–202

    Google Scholar 

  • Snyder SJ, Banerjee SP, Yamamura HI, Greenberg D (1974) Drugs, neurotransmitters and schizophrenia. Science 184:1243–1253

    CAS  Google Scholar 

  • Strube MJ, Hartmann DP (1983) Meta-analysis: techniques, applications, and functions. J Consult Clin Psychol 51:14–27

    Google Scholar 

  • Tecce JJ, Cole JO (1974) Amphetamine effects in man: paradoxical drowsiness and lowered electrical brain activity. Science 185:451–453

    Google Scholar 

  • Tune LE, Creese I, Coyle JT, Pearlson G, Snyder SH (1980) Low neuroleptic serum levels in patients receiving fluphenazine decanoate. Am J Psychiatry 137:80–82

    Google Scholar 

  • vanKammen D (1984) Amphetamine response in schizophrenia: An episode marker.: American Psychiatric Association 137th Annual Meeting, Los Angeles, California, pp 98–99

  • vanKammen DP, Bunney WE, Docherty JP, Jimerson DC, Post RM, Siris S, Ebert M, Gillin JC (1977) Amphetamine-induced catecholamine activation in schizophrenia and depression: behavioral and physiological effects. In: Costa E, Gessa GL (eds) Advances in biochemical psychopharmacology Vol. 16. Raven, New York, pp 655–659

    Google Scholar 

  • vanKammen D, Docherty J, Marder SR, Schulz SC, Bunnery WE (1980) Lack of behavioral supersensitivity to d-amphetamine after pimozide withdrawal. Arch Gen Psychiatry 37:287–290

    Google Scholar 

  • vanKammen D, Docherty J, Bunney W (1982a) Prediction of early relapse after pimozide discontinuation by response to d-amphetamine during pimozide treatment. Biol Psychiatry 17:233–242

    Google Scholar 

  • vanKammen D, Docherty J, Marder S, Rayner JN, Bunney WE (1982b) Long-term pimozide pretreatment differentially affects behavioral responses to dextroamphetamine in schizophrenia. Arch Gen Psychiatry 39:275–281

    Google Scholar 

  • vanKammen D, Docherty J, Marder S, Schulz SC, Dalton L (1982c) Antipsychotic effects of pimozide in schizophrenia. Arch Gen Psychiatry 39:261–266

    Google Scholar 

  • Wald D, Ebstein RP, Belmaker RH (1978) Haloperidol and lithium blocking of the mood response in intravenous methylphenidate. Psychopharmacology 57:93–97

    Google Scholar 

  • Weiner N (1980) Norepinephrine, epinephrine, and the sympathomimetic amines. In: Goodman LS, Gilman A (eds) The pharmacological basis of therapeutics. Macmillan, New York, pp 138–175

    Google Scholar 

  • Witton K (1960a) Directive psychotherapy with parenteral Ritalin in advanced schizophrenia. Dis Nerv Syst 21:681–685

    Google Scholar 

  • Witton K (1960b) Clinical observations on Ritlin HCL (methylphenidylacetate) injectable multiple dose vial. Am J Psychiatry 7:117–156

    Google Scholar 

  • Woolley LF (1938) The clinical effects of benzedrine sulfate in mental patients with retarded activity. Psychiatr Q 12:66–83

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hillside Hospital Division of Long Island Jewish Medical Center, PO Box 38, 11004, Glen Oaks, NY, USA

    J. A. Lieberman, J. M. Kane & J. Alvir

  2. SUNY, Stony Brook, NY, USA

    J. A. Lieberman & J. M. Kane

Authors
  1. J. A. Lieberman
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. M. Kane
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. J. Alvir
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Lieberman, J.A., Kane, J.M. & Alvir, J. Provocative tests with psychostimulant drugs in schizophrenia. Psychopharmacology 91, 415–433 (1987). https://doi.org/10.1007/BF00216006

Download citation

  • Received:

  • Revised:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF00216006

Key words

Search

Navigation

pFad - Phonifier reborn

Pfad - The Proxy pFad of © 2024 Garber Painting. All rights reserved.

Note: This service is not intended for secure transactions such as banking, social media, email, or purchasing. Use at your own risk. We assume no liability whatsoever for broken pages.


Alternative Proxies:

Alternative Proxy

pFad Proxy

pFad v3 Proxy

pFad v4 Proxy